Pregabalin Capsule
Product Images NDC 71610-820

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-820). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0820 30)

Pregabalin 50 mg oral capsules in a container of 30 capsules. The label includes storage instructions to keep between 68-77 degrees Fahrenheit and to store in a light-resistant container. It is manufactured by Aphena Pharma Solutions - Tennessee, LLC. The label displays the NDC 71610-820-30 and includes a warning to keep out of reach of children.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure of pregabalin, showing its molecular arrangement with a CO2H group and an NH2 group attached to a carbon chain, consistent with its generic formulation.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin at dosages of 25 mg, 100 mg, and 200 mg taken three times a day, against a placebo. The graph shows trends of patient improvement corresponding to increasing percent pain relief.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph depicting the percent of patients improved plotted against the percent improvement in pain from baseline. The graph compares outcomes for two groups: patients receiving Pregabalin 100 mg three times a day and patients receiving a placebo. Pregabalin shows a higher percent of patients improved across the range of pain improvement from baseline compared to placebo.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice daily, compared to placebo. The graph illustrates higher patient improvement rates associated with increasing Pregabalin doses.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph comparing percent improvement in pain from baseline against the percent of patients improved for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The x-axis shows percent improvement in pain, and the y-axis shows percent of patients improved with three different line styles representing each group.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph showing the percent of patients improved over a range of values from greater than 0 to 100. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, using different line styles for each group.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar graph depicting responder rates (%) in two clinical trials labeled Study E1 and Study E3. The x-axis shows different treatment groups including placebo and various dosages of pregabalin taken BID or TID. The y-axis displays responder rates ranging from 0% to 60%. Study E1 shows increasing responder rates from placebo at 14% to 51% at 600 mg/day BID. Study E3 indicates responder rates from placebo at 9% to 49% at 600 mg/day TID.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph displaying seizure reduction as median percent change from baseline across different doses of Pregabalin (mg/day). It compares results from three studies (E1, E2, E3) with BID and TID dosing schedules, showing increasing seizure reduction with dose. Significant p-values are noted for various dose points, indicating statistically significant seizure reduction versus placebo.*

FDA Label Image

Figure 9 (Pregabalin 09)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin daily doses of 600 mg, 450 mg, and 300 mg, as well as a placebo group, indicating trends in patient improvement over varying levels of pain reduction.*

FDA Label Image

Figure 10 (Pregabalin 10)

A Kaplan-Meier survival curve comparing Pregabalin versus Placebo over 180 days. The y-axis shows the estimated percentage of subjects without LTR (loss to response), and the x-axis shows time in days. The solid line represents Pregabalin, and the dashed line represents Placebo.*

FDA Label Image

Figure 11 (Pregabalin 11)

A line graph comparing the percent of subjects improved over time from baseline to Week 12, showing results for Pregabalin and placebo groups. The x-axis represents the percent improvement, and the y-axis shows the percent of subjects improved, with separate curves for Pregabalin and placebo treatment groups.*

FDA Label Image

Figure 12 (Pregabalin 12)

A line graph depicting the percent of subjects improved over time from baseline to week 16, comparing Pregabalin and Placebo. The x-axis represents the percent improved from baseline to week 16, while the y-axis shows the percent of subjects improved. Two lines illustrate the results for Pregabalin and Placebo groups over the study period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.